Marathon Trading Investment Management LLC Makes New Investment in Humana Inc. (NYSE:HUM)

Marathon Trading Investment Management LLC acquired a new position in Humana Inc. (NYSE:HUM - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,580 shares of the insurance provider's stock, valued at approximately $1,162,000.

Several other institutional investors also recently modified their holdings of HUM. State Street Corp grew its holdings in Humana by 1.0% during the 3rd quarter. State Street Corp now owns 5,357,420 shares of the insurance provider's stock worth $1,701,582,000 after acquiring an additional 53,272 shares during the period. FMR LLC boosted its position in shares of Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider's stock worth $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Pzena Investment Management LLC lifted its position in Humana by 8.1% in the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider's stock valued at $793,830,000 after acquiring an additional 187,903 shares in the last quarter. Ontario Teachers Pension Plan Board lifted its position in Humana by 6.5% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider's stock valued at $371,705,000 after acquiring an additional 71,910 shares in the last quarter. Finally, Sanders Capital LLC lifted its position in Humana by 1.0% in the 3rd quarter. Sanders Capital LLC now owns 1,168,341 shares of the insurance provider's stock valued at $370,060,000 after acquiring an additional 11,923 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Remove Ads

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company's stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.32% of the stock is currently owned by insiders.

Humana Price Performance

Shares of HUM traded down $1.04 during mid-day trading on Tuesday, reaching $250.21. 1,387,813 shares of the stock traded hands, compared to its average volume of 1,676,635. The firm has a fifty day moving average price of $271.67 and a 200 day moving average price of $281.65. The company has a market cap of $30.19 billion, a price-to-earnings ratio of 25.15, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities research analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.41%. Humana's dividend payout ratio (DPR) is currently 35.58%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on HUM shares. StockNews.com cut shares of Humana from a "buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. Morgan Stanley dropped their target price on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Finally, Truist Financial lifted their target price on shares of Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a research report on Monday, January 6th. Twenty equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.